PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Research unit

INNOSUISSE

Project number

132.767 IP-LS

Project title

PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Biotechnology and processing
Abstract (English)	InCephalo is a preclinical-stage biotech company developing innovative therapies for CNS diseases. This project focuses on advancing the C-Lock platform by developing glycan-optimized variants of biologics, enabling tunable systemic half-life without compromising activity.